In 2021, Serum Institute of India Pvt. Ltd. subsidiary Serum Institute of Life Sciences (SILS) entered a deal with Biocon, Ltd. arm Biocon Biologics to acquire a 15% stake in exchange for a $150m cash infusion and access to a vaccine pipeline that would have included COVID-19 and other vaccines.
Serum-Biocon Deal Sees COVID Reality Tweak Even As Oxford’s Malaria Vaccine Holds Promise
HPV Vaccine India Tender Keenly Awaited
Gains from its COVID-19 vaccine made Serum Institute’s founder the world’s richest healthcare billionaire. But the demand for boosters hasn’t materialized as expected, leading to a deal with Biocon being tweaked. Meanwhile, gains from India’s first indigenously-developed HPV vaccine and Oxford-partnered malaria vaccine seem imminent.
More from Antiparasitic
More from Scrip
• By
Senior executives from AstraZeneca, BMS, Novo Nordisk, Takeda and Regeneron outline how big pharma's global capability centers (GCCs) in India are evolving beyond cost efficiency, focusing on innovation, “agile experimentation” and new technology including GenAI, virtual & augmented reality, with some positioned as COEs. Will Indian multinationals use the GCC approach?
• By
In this week's episode: Merck & Co. licenses Hengrui’s lipid lowerer; Novo gets United’s triple G obesity drug; J&J plans major US manufacturing investments; approval for GSK’s novel antibiotic; and a call for more aggressive Korean M&A activity.
• By
Plus deals involving GV20/Mitsubishi Tanabe, Kaken/Alumis, AstraZeneca/Alteogen and deal terminations involving Clover/Gavi Alliance and Rhythm/RareStone.